| |
| |
|
| Insider
Information: |
Collard Craig A |
| Relationship: |
|
| City: |
Cary |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
262,793 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$643,843 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
262,793 |
|
|
| Total
Value |
$643,843 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
9
|
0
|
|
Stock
price went up :
|
7
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
3.5
|
0.0
|
| Percentage
Gain/Loss : |
 77.9%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Opiant Pharmaceuticals Inc |
OPNT |
Director |
2023-03-02 |
0 |
2020-06-15 |
0 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director |
2022-07-01 |
0 |
2021-11-23 |
0 |
Premium* |
|
|
Heron Therapeutics Inc |
HRTX |
|
2024-04-19 |
262,793 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HRTX |
Heron Therapeutics Inc |
Chief Executive Officer |
• • – |
2024-04-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,797 |
262,793 |
0 |
- |
|
| HRTX |
Heron Therapeutics Inc |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,500 |
248,996 |
0 |
- |
|
| HRTX |
Heron Therapeutics Inc |
Chief Executive Officer |
• • – |
2023-11-16 |
4 |
B |
$0.92 |
$137,970 |
D/D |
150,000 |
186,496 |
2.81 |
% |
|
| HRTX |
Heron Therapeutics Inc |
Chief Executive Officer |
• • – |
2023-08-22 |
4 |
D |
$1.65 |
$1,142 |
D/D |
(692) |
36,496 |
0 |
- |
|
| HRTX |
Heron Therapeutics Inc |
Chief Executive Officer |
• • – |
2023-05-22 |
4 |
D |
$1.45 |
$1,002 |
D/D |
(691) |
37,188 |
0 |
- |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2023-03-02 |
4 |
D |
$20.00 |
$1,116,440 |
D/D |
(55,822) |
0 |
0 |
- |
|
| HRTX |
Heron Therapeutics Inc |
Director |
– • – |
2023-02-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
37,879 |
|
% |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2022-07-01 |
4 |
D |
$55.00 |
$742,500 |
D/D |
(13,500) |
0 |
0 |
- |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2022-06-13 |
4 |
B |
$10.94 |
$44,149 |
D/D |
4,037 |
53,822 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2022-06-10 |
4 |
B |
$11.50 |
$19,118 |
D/D |
1,663 |
49,785 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2022-05-16 |
4 |
B |
$13.54 |
$367,611 |
D/D |
27,150 |
48,122 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2022-05-13 |
4 |
B |
$10.49 |
$38,698 |
D/D |
3,689 |
20,972 |
2.39 |
% |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2021-11-24 |
4 |
B |
$23.09 |
$182,348 |
D/D |
7,899 |
13,500 |
2.39 |
% |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2021-11-23 |
4 |
B |
$22.95 |
$128,515 |
D/D |
5,601 |
5,601 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2021-09-13 |
4 |
A |
$17.96 |
$21,737 |
D/D |
1,206 |
17,283 |
0 |
- |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2021-09-13 |
4 |
B |
$18.13 |
$45,325 |
D/D |
2,500 |
16,077 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2021-09-10 |
4 |
B |
$18.18 |
$174,110 |
D/D |
9,577 |
13,577 |
2.39 |
% |
|
| OPNT |
Opiant Pharmaceuticals In... |
Director |
– • – |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
0 |
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
